Brief: Unity Biotechnology Provides Program Updates And Anticipated Milestones For 2022
04/01/2022 13:17
Jan 4 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY PROVIDES PROGRAM UPDATES AND
ANTICIPATED
MILESTONES FOR 2022
* UNITY BIOTECHNOLOGY INC - 12-WEEK SAFETY & EFFICACY
ANALYSIS
FROM PHASE 2 STUDY OF UBX1325 IN DIABETIC MACULAR EDEMA (DME)
EXPECTED IN FIRST HALF 2022
Source text for Eikon: ID:nGNX5YtvLj
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force